PASC

Study Designs Completed for NIH Consortium Study of Long-term COVID-19

Wednesday, September 15, 2021 - 4:41pm

As the CSC for the NIH grant, NYU Langone is charged with integrating the research activities of clinical sites around the country.

Key Points: 
  • As the CSC for the NIH grant, NYU Langone is charged with integrating the research activities of clinical sites around the country.
  • As of August 25, more than 39 million Americans had been infected with COVID-19, resulting in 648,000 deaths.
  • The study will also seek to enroll participants without SARS-CoV-2 infection to serve as a comparison group.
  • An important aspect of the RECOVER Initiative is the development of the pediatric main protocol for study of Long COVID in children.

CytoDyn to Present at Emerging Growth Conference on September 15 Follow by Live Q/A

Monday, September 13, 2021 - 11:00am

The conference sponsor provides corporate visibility services to CytoDyn for a fee.

Key Points: 
  • The conference sponsor provides corporate visibility services to CytoDyn for a fee.
  • The first indication is combination therapy with HAART for HIV-infected patients, and the second is for metastatic triple-negative breast cancer (mTNBC).
  • It binds to CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells.
  • Leronlimab does not work on other strains of HIV (for example X4), however, R5 is the most dominant strain of HIV.

Mymee to Host Virtual COVID-19 and Autoimmunity Summit from September 13 - 24, 2021

Friday, September 10, 2021 - 3:00pm

Millions more suffer from COVID long haul or Post Acute Sequelae of COVID (PASC), resulting in persistent, unresolved symptoms, often resembling autoimmunity, weeks or months after recovering from the virus.

Key Points: 
  • Millions more suffer from COVID long haul or Post Acute Sequelae of COVID (PASC), resulting in persistent, unresolved symptoms, often resembling autoimmunity, weeks or months after recovering from the virus.
  • Mymee's real world program results have shown an improvement in severe symptoms and improved quality of life after 8 weeks.
  • 79% Mymee members see reductions in common autoimmunity symptoms like fatigue, brain fog and pain within the first 8 weeks.
  • Mymee is a preferred network partner of Mount Sinai Hospital and a recent recipient of Fast Company's 2021 the World Changing Ideas Awards.

Groups Tackle Vaccinations to Create #COVIDSafeZones at College Game Days

Thursday, August 26, 2021 - 7:09pm

WASHINGTON, Aug. 26, 2021 /PRNewswire/ -- Bipartisan leaders and health experts are calling for #COVIDSafeZones on college game days as the college football season begins and the COVID-19 Delta Variant spreads.

Key Points: 
  • WASHINGTON, Aug. 26, 2021 /PRNewswire/ -- Bipartisan leaders and health experts are calling for #COVIDSafeZones on college game days as the college football season begins and the COVID-19 Delta Variant spreads.
  • In a new letter, the COVID Collaborative provides recommendations for college and university leadership to use the energy and spirit of the college football season to increase vaccinations in communities.
  • The COVID Collaborative and Autonomy 5 Conferences have also put out a statement on #COVIDSafeZones and game day safety endorsed by the medical directors of the major college sports leagues.
  • The COVID Collaborative has #COVIDSafeZones campaigns with the business community, higher education, and college sports.

First Long COVID Dashboard Released By The American Academy Of Physical Medicine And Rehabilitation

Tuesday, August 24, 2021 - 3:05pm

ROSEMONT, Ill., Aug. 24, 2021 /PRNewswire/ -- The American Academy of Physical Medicine and Rehabilitation (AAPM&R) today announced the launch of the first dashboard that shows how many millions of Americans are estimated to be experiencing Long COVID symptoms by state, county and nationally.

Key Points: 
  • ROSEMONT, Ill., Aug. 24, 2021 /PRNewswire/ -- The American Academy of Physical Medicine and Rehabilitation (AAPM&R) today announced the launch of the first dashboard that shows how many millions of Americans are estimated to be experiencing Long COVID symptoms by state, county and nationally.
  • AAPM&R's dashboard has options for estimating the number of Long COVID cases based on different assumptions and percentages.
  • On August 6, AAPM&R released the first Long COVID guidance statement on fatigue , which is a peer-reviewed guidance statement intended to help physicians make clinical decisions concerning treatment of Long COVID.
  • The American Academy of Physical Medicine and Rehabilitation is the national medical specialty organization representing more than 10,000 physicians who are specialists in physical medicine and rehabilitation.

First Long COVID Guidance Statement on Fatigue Released By American Academy of Physical Medicine and Rehabilitation

Friday, August 6, 2021 - 9:57pm

The first fatigue guidance statement is published as an article in the PM&R Journal.

Key Points: 
  • The first fatigue guidance statement is published as an article in the PM&R Journal.
  • "Fatigue during an acute viral illness is common, however individuals with PASC are often presenting with long lasting and debilitating fatigue after recovery.
  • We're hopeful that this essential guidance will make a significant difference for long COVID patients who are experiencing fatigue," said Talya Fleming, MD, FAAPMR, co-author of the fatigue guidance statement.
  • The American Academy of Physical Medicine and Rehabilitation is the national medical specialty organization representing more than 10,000 physicians who are specialists in physical medicine and rehabilitation.

CytoDyn Receives Clearance from Brazil’s ANVISA to Commence Phase 3 Trial for Severe COVID-19 Patients

Tuesday, August 3, 2021 - 11:00am

This Phase 3 trial will be conducted in up to 35 clinical sites with 612 patients who are hospitalized and in need of oxygenation support.

Key Points: 
  • This Phase 3 trial will be conducted in up to 35 clinical sites with 612 patients who are hospitalized and in need of oxygenation support.
  • Additionally, ANVISA is reviewing another protocol submitted for a second clinical trial for 316 critically ill COVID-19 patients.
  • After completing two clinical trials with COVID-19 patients (a Phase 2 and a Phase 3), CytoDyn initiated a Phase 2 investigative trial for post-acute sequelae of SARS COV-2 (PASC), also known as COVID-19 Long-Haulers.
  • CytoDyn also completed a Phase 2b/3 investigative trial with leronlimab used as a once-weekly monotherapy for HIV-infected patients.

Organicell Announces FDA Approval Of IND Application For The Use Of Zofin™ In COVID-19 Long Haulers

Wednesday, July 21, 2021 - 12:55pm

This approved trial design consists of a double blinded, placebo-controlled, randomized phase I/II trial designed to investigate the safety and potential efficacy of Zofin in treating COVID-19 long haulers.

Key Points: 
  • This approved trial design consists of a double blinded, placebo-controlled, randomized phase I/II trial designed to investigate the safety and potential efficacy of Zofin in treating COVID-19 long haulers.
  • These patients, called COVID-19 "long haulers," report lingering shortness of breath, cough, fatigue, and mental fog for months after recovery, impairing their return to work and everyday life.
  • Even by the lowest health care industry estimates, the magnitude of this secondary health crisis of COVID-19 long haulers will result in millions of affected individuals.
  • Organicell has no intention and specifically disclaims any duty to update the information in this press release.

IncellDx: Two New Studies Offer a First Model for Diagnosing, Monitoring and Treating Long COVID

Wednesday, July 14, 2021 - 4:00pm

Two new studies propose the first model for diagnosing, indexing and monitoring Post-Acute Sequelae of COVID-19 (PASC), also known as long COVID or long haul COVID.

Key Points: 
  • Two new studies propose the first model for diagnosing, indexing and monitoring Post-Acute Sequelae of COVID-19 (PASC), also known as long COVID or long haul COVID.
  • The findings also provide a framework for understanding the cause of, and potential treatment for, long COVID.
  • Long COVID is believed to affect as many as 30 percent of people who have recovered from initial infection with COVID-19.
  • Taken together, findings from these two studies provide an objective and measurable model for understanding whats happening and why long COVID patients continue to experience symptoms long after initial COVID infection, and why those symptoms are so diverse and widespread.

Tonix Pharmaceuticals Announces Program to Develop TNX-102 SL for the Treatment of Long COVID Syndrome, also Known as Post-Acute Sequelae of COVID-19 (PASC)

Monday, June 21, 2021 - 12:00pm

Although most people recover from COVID-19 within weeks of the acute illness, a substantial portion develop a chronic syndrome called Long COVID, or PASC.

Key Points: 
  • Although most people recover from COVID-19 within weeks of the acute illness, a substantial portion develop a chronic syndrome called Long COVID, or PASC.
  • Most Long COVID patients who have been studied appear to have cleared the SARS-CoV-2 virus from their systems.
  • By improving sleep quality, we believe TNX-102 SL may improve the sleep disturbance of Long COVID and potentially also improve other symptoms of Long COVID.
  • For example, TNX-102 SL showed activity in addressing persistent pain, sleep disturbance and fatigue in our fibromyalgia Phase 3 study.